MILPITAS, Calif., June 24, 2025 — Applied StemCell, a leading provider of advanced stem cell and gene editing technologies since 2008, today announced the release of hiEX™ Research iPSC Exosomes, a new research-use-only product designed to enable scientists to explore the therapeutic potential of iPSC-derived exosomes in areas such as wound healing, aging, and nerve regeneration. [Read more…]
Winner of the “Biotherapies and Bioproduction” Call for Projects Under the France 2030 plan, EVerZom Receives €3M in Government Funding to Industrialize its Exosome Bioproduction Technology
Paris, June 17, 2025 – EVerZom, a French biopharmaceutical company pioneering exosome-based therapies for regenerative medicine applications, has announced it has received €3 million in funding as part of the France 2030 plan, through the “Biotherapies and Bioproduction of Innovative Therapies” call for projects, operated by Bpifrance on behalf of the French government. This financial support will enable the company to accelerate the industrialization of its exosome bioproduction platform to develop its proprietary and co-developed drug candidates. [Read more…]
L2 Bio Seeks Principal Investigators for FDA-Approved Phase 2B Clinical Trial of Adipose-Derived Stem Cell Treatment for Crohn’s Disease
HENDERSON, NV – June 12, 2025, www.L2Bio.com – L2 Bio, is the clear leader in adipose-derived stem cell banking. L2 Bio is the only AD-Stem Cell Banking company with an FDA Approved Investigational New Drug. L2 is actively recruiting qualified Principal Investigators for its recently FDA-approved Phase 2B clinical trial. This groundbreaking study will investigate a novel intravenous (IV) delivery of adipose-derived stem cells (ADSCs or ASCs) for the treatment of Crohn’s Disease utilizing autologous or first-degree blood relative sourced Adipose Derived Mesenchymal Stem Cells (AD-MSCs). A simple, virtually painless, 15-minute procedure from the subject or donor is likely to produce enough stem cells to treat the subject for the duration of the trial and likely the remainder of their life if necessary. [Read more…]
UniXell does first patient with an autologous iPSC-based cell therapy (UX-DA001) for Parkinson’s disease in Phase 1 study
SHANGHAI, May 23, 2025 — Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first administration of its proprietary Parkinson’s disease cell drug UX-DA001 in China in March 2025. The Phase I clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of UX-DA001 in patients with Parkinson’s disease. [Read more…]
Applied StemCell Launches Two New Hypoimmunogenic hiPSC Products to Accelerate Allogeneic Cell Therapy Development
MILPITAS, Calif. — Applied StemCell, a CRO/CDMO that blends unique genome editing technology and iPSC expertise, announced the launch of their first hypoimmunogenic hiPSC products which are designed to empower researchers developing next-generation allogeneic cell therapies. The ActiCells™ RUO Hypo hiPSCs (Cat.# ASE-9550) and the ActiCells™ RUO TARGATT™ Hypo hiPSC Knock-in Kit (Cat.# AST-9650) offer powerful tools for building off-the-shelf therapies by combining reduced immunogenicity, robust pluripotency, and genome engineering readiness. They are an isogenic match to the forthcoming GMP-grade versions to offer a seamless path from early research to clinical development. [Read more…]
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 119
- Next Page »